Has Matthew Mellon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $159,307 in general payments to Matthew Mellon, MD across 203 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Mellon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Mellon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Mellon, MD

Urology · Carmel, INNPI 1841457439

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 98.5% of it on its own, with 8 other manufacturers making up the rest. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$159,307in general payments, 2019–2025

Across 203 payments — averaging $784.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$157K
Cook Incorporated$2K
Coloplast$200
Kerecis Limited$176
Axonics, Inc.$76
Antares Pharma, Inc.$50
plus $68 from 3 others

$26,925in research payments, 2019–2025

Across 4 payments — averaging $6731.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$27K

What the payments were for

Consulting fees$54,01034%
Speaking & faculty fees$78,51349%
Travel & lodging$20,57313%
Food & beverage$6,0884%
Education$1230%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	193	$156,878
Cook Incorporated	3	$1,860
Coloplast	1	$200
Kerecis Limited	1	$176
Axonics, Inc.	1	$76
Antares Pharma, Inc.	1	$50
AstraZeneca	1	$35
Urogen Pharma, Inc.	1	$18
Pfizer	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TACTRA$32,059
AdVance XP$28,976
GENERAL ERECTILE DYSFUNCTION$15,474
AMS 700 CXR RTE KIT$12,213
AMS$10,610
OPTIFLEX$8,000
ADVANCE$5,319
AMS 700$3,762
GENERAL - THERAPIES$3,407
AMS 800 Artificial Urinary Sphincter$1,198
Kerecis SurgiClose$702
TITAN$200
Kerecis GraftGuide$176

How this compares

$159,307 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana →

Medicare billing

Part B allowed, 2024

$131,902

Medicare patients

259

Services billed

1,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	51	$32,428
GemtesaVibegron	15	$11,872
Tolterodine Tartrate ErTolterodine Tartrate	33	$4,787
Testosterone	18	$3,925
Tamsulosin Hcl	121	$1,791
Testosterone Cypionate	47	$1,493
Oxybutynin Chloride ErOxybutynin Chloride	34	$1,071
Trospium Chloride	16	$884
Alfuzosin Hcl ErAlfuzosin Hcl	21	$406
Cephalexin	65	$372
Finasteride	30	$303
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	47	$283
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	41	$253
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	43	$217
Ciprofloxacin Hcl	14	$93

Paid to pharmacies, not to this prescriber.

Other urology in Carmel

Alexander TatemCarmel$418K
Chad ReichardCarmel$400K
Jason KovacCarmel$112K
Kenneth NeyCarmel$55K
Jeremiah DallmerCarmel$52K
Scott FarnhamCarmel$30K
Megan BockCarmel$28K
Joshua RingCarmel$13K
Clinton BahlerCarmel$11K
Scott PikeCarmel$11K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →